We report, here, our results of the treatment of control and sporadic ALS lymphoblasts with Tideglusib, an in-house designed non-ATP competitive GSK-3β inhibitor, that have shown good safety and tolerability in patients with different neurological diseases [23,24,25,26,34]. The gene discussed is GSK3B; the disease is amyotrophic lateral sclerosis.